ID   CDK7_HUMAN              Reviewed;         346 AA.
AC   P50613; Q9BS60; Q9UE19;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   05-OCT-2010, entry version 129.
DE   RecName: Full=Cell division protein kinase 7;
DE            EC=2.7.11.22;
DE            EC=2.7.11.23;
DE   AltName: Full=39 kDa protein kinase;
DE   AltName: Full=CAK1;
DE   AltName: Full=CDK-activating kinase;
DE            Short=CAK;
DE   AltName: Full=STK1;
DE   AltName: Full=TFIIH basal transcription factor complex kinase subunit;
DE   AltName: Full=p39 Mo15;
GN   Name=CDK7; Synonyms=MO15;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   MEDLINE=95014737; PubMed=7929589; DOI=10.1083/jcb.127.2.467;
RA   Tassan J.-P., Schultz S.J., Bartek J., Nigg E.A.;
RT   "Cell cycle analysis of the activity, subcellular localization, and
RT   subunit composition of human CAK (CDK-activating kinase).";
RL   J. Cell Biol. 127:467-478(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Mammary gland;
RX   MEDLINE=94268838; PubMed=8208544;
RA   Levedakou E.N., He M., Baptist E.W., Craven R.J., Cance W.G.,
RA   Welcsh P.L., Simmons A., Naylor S.L., Leach R.J., Lewis T.B.,
RA   Bowcock A., Liu E.T.;
RT   "Two novel human serine/threonine kinases with homologies to the cell
RT   cycle regulating Xenopus MO15, and NIMA kinases: cloning and
RT   characterization of their expression pattern.";
RL   Oncogene 9:1977-1988(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=95022621; PubMed=7936635;
RA   Darbon J.-M., Devault A., Taviaux S., Fesquet D., Martinez A.-M.,
RA   Galas S., Cavadore J.-C., Doree M., Blanchard J.-M.;
RT   "Cloning, expression and subcellular localization of the human homolog
RT   of p40MO15 catalytic subunit of cdk-activating kinase.";
RL   Oncogene 9:3127-3138(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fibroblast;
RX   MEDLINE=94268852; PubMed=8208556;
RA   Wu L., Yee A., Liu L., Carbonaro-Hall D., Venkatesan N., Tolo T.,
RA   Hall F.L.;
RT   "Molecular cloning of the human CAK1 gene encoding a cyclin-dependent
RT   kinase-activating kinase.";
RL   Oncogene 9:2089-2096(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung, and Thymus;
RA   Kobelt D., Karn T., Hock B., Holtrich U., Braeuninger A., Wolf G.,
RA   Strebhardt K., Ruebsamen-Waigmann H.;
RT   "Human and Xenopus MO15 mRNA are highly conserved but show different
RT   patterns of expression in adult tissues.";
RL   Oncol. Rep. 1:1269-1275(1994).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ALA-163 AND MET-285.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cervix, and Urinary bladder;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   MUTAGENESIS OF THR-170.
RX   MEDLINE=94349374; PubMed=8069918; DOI=10.1016/0092-8674(94)90535-5;
RA   Fisher R.P., Morgan D.O.;
RT   "A novel cyclin associates with MO15/CDK7 to form the CDK-activating
RT   kinase.";
RL   Cell 78:713-724(1994).
RN   [9]
RP   PHOSPHORYLATION AT SER-164 AND THR-170, AND MUTAGENESIS OF SER-164 AND
RP   THR-170.
RX   MEDLINE=99051317; PubMed=9832506;
RA   Akoulitchev S., Reinberg D.;
RT   "The molecular mechanism of mitotic inhibition of TFIIH is mediated by
RT   phosphorylation of CDK7.";
RL   Genes Dev. 12:3541-3550(1998).
RN   [10]
RP   IDENTIFICATION IN THE TFIIH BASAL TRANSCRIPTION FACTOR.
RX   PubMed=9852112; DOI=10.1074/jbc.273.51.34444;
RA   Kershnar E., Wu S.-Y., Chiang C.-M.;
RT   "Immunoaffinity purification and functional characterization of human
RT   transcription factor IIH and RNA polymerase II from clonal cell lines
RT   that conditionally express epitope-tagged subunits of the multiprotein
RT   complexes.";
RL   J. Biol. Chem. 273:34444-34453(1998).
RN   [11]
RP   FUNCTION.
RX   MEDLINE=99149021; PubMed=10024882; DOI=10.1016/S1097-2765(00)80177-X;
RA   Tirode F., Busso D., Coin F., Egly J.-M.;
RT   "Reconstitution of the transcription factor TFIIH: assignment of
RT   functions for the three enzymatic subunits, XPB, XPD, and cdk7.";
RL   Mol. Cell 3:87-95(1999).
RN   [12]
RP   INTERACTION WITH PUF60.
RX   MEDLINE=20337922; PubMed=10882074; DOI=10.1016/S1097-2765(00)80428-1;
RA   Liu J., He L., Collins I., Ge H., Libutti D., Li J., Egly J.-M.,
RA   Levens D.;
RT   "The FBP interacting repressor targets TFIIH to inhibit activated
RT   transcription.";
RL   Mol. Cell 5:331-341(2000).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-164 AND THR-170, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=17192257; DOI=10.1074/mcp.T600062-MCP200;
RA   Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R.,
RA   Keri G., Wehland J., Daub H.;
RT   "Proteomics analysis of protein kinases by target class-selective
RT   prefractionation and tandem mass spectrometry.";
RL   Mol. Cell. Proteomics 6:537-547(2007).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-170, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-7; SER-164; THR-170;
RP   THR-287 AND SER-321, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-164 AND THR-170, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-169 AND THR-170, AND
RP   MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-170, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (3.02 ANGSTROMS) IN COMPLEX WITH ATP, ACTIVE
RP   SITE, AND PHOSPHORYLATION AT THR-170.
RX   PubMed=15530371; DOI=10.1016/j.str.2004.08.013;
RA   Lolli G., Lowe E.D., Brown N.R., Johnson L.N.;
RT   "The crystal structure of human CDK7 and its protein recognition
RT   properties.";
RL   Structure 12:2067-2079(2004).
RN   [21]
RP   VARIANT [LARGE SCALE ANALYSIS] MET-285.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Cyclin-dependent kinases (CDKs) are activated by the
CC       binding to a cyclin and mediate the progression through the cell
CC       cycle. Each different complex controls a specific transition
CC       between two subsequent phases in the cell cycle. CDK7 is the
CC       catalytic subunit of the CDK-activating kinase (CAK) complex, a
CC       serine-threonine kinase. CAK activates the cyclin-associated
CC       kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation.
CC       CAK complexed to the core-TFIIH basal transcription factor
CC       activates RNA polymerase II by serine phosphorylation of the
CC       repetitive C-terminus domain (CTD) of its large subunit (POLR2A),
CC       allowing its escape from the promoter and elongation of the
CC       transcripts. Involved in cell cycle control and in RNA
CC       transcription by RNA polymerase II. Its expression and activity
CC       are constant throughout the cell cycle.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- CATALYTIC ACTIVITY: ATP + [DNA-directed RNA polymerase] = ADP +
CC       [DNA-directed RNA polymerase] phosphate.
CC   -!- ENZYME REGULATION: Inactivated by phosphorylation.
CC   -!- SUBUNIT: Associates primarily with cyclin H and MAT1 to form the
CC       CAK complex. CAK can further associate with the core-TFIIH to form
CC       the TFIIH basal transcription factor. Interacts with PUF60.
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- PTM: Phosphorylation of Ser-164 during mitosis inactivates the
CC       enzyme.
CC   -!- PTM: Phosphorylation of Thr-170 is required for activity.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. CDC2/CDKX subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cdk7/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X79193; CAA55785.1; -; mRNA.
DR   EMBL; L20320; AAA36657.1; -; mRNA.
DR   EMBL; X77743; CAA54793.1; -; mRNA.
DR   EMBL; X77303; CAA54508.1; -; mRNA.
DR   EMBL; Y13120; CAA73587.1; -; mRNA.
DR   EMBL; AY130859; AAM77799.1; -; Genomic_DNA.
DR   EMBL; BC000834; AAH00834.1; -; mRNA.
DR   EMBL; BC005298; AAH05298.1; -; mRNA.
DR   IPI; IPI00000685; -.
DR   PIR; A54820; A54820.
DR   PIR; I37215; I37215.
DR   RefSeq; NP_001790.1; -.
DR   UniGene; Hs.184298; -.
DR   PDB; 1LG3; Model; -; A=1-307.
DR   PDB; 1PA8; Model; -; A=181-346.
DR   PDB; 1UA2; X-ray; 3.02 A; A/B/C/D=1-346.
DR   PDB; 2HIC; Model; -; B=13-311.
DR   PDBsum; 1LG3; -.
DR   PDBsum; 1PA8; -.
DR   PDBsum; 1UA2; -.
DR   PDBsum; 2HIC; -.
DR   ProteinModelPortal; P50613; -.
DR   DIP; DIP-5995N; -.
DR   IntAct; P50613; 17.
DR   STRING; P50613; -.
DR   PhosphoSite; P50613; -.
DR   PeptideAtlas; P50613; -.
DR   PRIDE; P50613; -.
DR   Ensembl; ENST00000256443; ENSP00000256443; ENSG00000134058.
DR   GeneID; 1022; -.
DR   KEGG; hsa:1022; -.
DR   NMPDR; fig|9606.3.peg.25336; -.
DR   UCSC; uc003jvs.2; human.
DR   CTD; 1022; -.
DR   GeneCards; GC05P068530; -.
DR   HGNC; HGNC:1778; CDK7.
DR   HPA; CAB004364; -.
DR   HPA; HPA007932; -.
DR   MIM; 601955; gene.
DR   PharmGKB; PA26314; -.
DR   eggNOG; prNOG09228; -.
DR   HOGENOM; HBG755340; -.
DR   HOVERGEN; HBG014652; -.
DR   InParanoid; P50613; -.
DR   OMA; FMDTDLE; -.
DR   OrthoDB; EOG980MGK; -.
DR   PhylomeDB; P50613; -.
DR   BRENDA; 2.7.11.22; 247.
DR   BRENDA; 2.7.11.23; 247.
DR   Pathway_Interaction_DB; retinoic_acid_pathway; Retinoic acid receptors-mediated signaling.
DR   Reactome; REACT_152; Cell Cycle, Mitotic.
DR   Reactome; REACT_1675; mRNA Processing.
DR   Reactome; REACT_1788; Transcription.
DR   Reactome; REACT_216; DNA Repair.
DR   Reactome; REACT_6185; HIV Infection.
DR   Reactome; REACT_71; Gene Expression.
DR   BindingDB; P50613; -.
DR   NextBio; 4295; -.
DR   ArrayExpress; P50613; -.
DR   Bgee; P50613; -.
DR   CleanEx; HS_CDK7; -.
DR   Genevestigator; P50613; -.
DR   GermOnline; ENSG00000134058; Homo sapiens.
DR   GO; GO:0005675; C:holo TFIIH complex; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0050681; F:androgen receptor binding; NAS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004693; F:cyclin-dependent protein kinase activity; TAS:ProtInc.
DR   GO; GO:0008094; F:DNA-dependent ATPase activity; IDA:UniProtKB.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0008353; F:RNA polymerase II carboxy-terminal domain k...; IDA:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; NAS:UniProtKB.
DR   GO; GO:0030521; P:androgen receptor signaling pathway; NAS:UniProtKB.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0000718; P:nucleotide-excision repair, DNA damage removal; EXP:Reactome.
DR   GO; GO:0045944; P:positive regulation of transcription from R...; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IEA:InterPro.
DR   GO; GO:0000079; P:regulation of cyclin-dependent protein kina...; TAS:ProtInc.
DR   GO; GO:0006368; P:RNA elongation from RNA polymerase II promoter; EXP:Reactome.
DR   GO; GO:0006367; P:transcription initiation from RNA polymeras...; EXP:Reactome.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell cycle; Cell division;
KW   Complete proteome; DNA damage; DNA repair; Kinase; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Polymorphism;
KW   Serine/threonine-protein kinase; Transcription;
KW   Transcription regulation; Transferase.
FT   CHAIN         1    346       Cell division protein kinase 7.
FT                                /FTId=PRO_0000085791.
FT   DOMAIN       12    295       Protein kinase.
FT   NP_BIND      18     26       ATP.
FT   ACT_SITE    137    137       Proton acceptor.
FT   BINDING      41     41       ATP.
FT   MOD_RES       7      7       Phosphoserine.
FT   MOD_RES     164    164       Phosphoserine.
FT   MOD_RES     169    169       Phosphotyrosine.
FT   MOD_RES     170    170       Phosphothreonine.
FT   MOD_RES     287    287       Phosphothreonine.
FT   MOD_RES     321    321       Phosphoserine.
FT   VARIANT     163    163       G -> A.
FT                                /FTId=VAR_023118.
FT   VARIANT     285    285       T -> M (in dbSNP:rs34584424).
FT                                /FTId=VAR_023119.
FT   MUTAGEN      41     41       K->A: Total loss of activity.
FT   MUTAGEN     164    164       S->A: No mitotic repression of
FT                                transcriptional activity of the
FT                                reconstituted TFIIH complex.
FT   MUTAGEN     170    170       T->A: Total loss of activity. Total loss
FT                                of transcriptional activity of the
FT                                reconstituted TFIIH complex.
FT   CONFLICT    130    130       Q -> R (in Ref. 7; AAH05298).
FT   CONFLICT    249    249       F -> C (in Ref. 5; CAA73587).
FT   CONFLICT    321    321       S -> A (in Ref. 5; CAA73587).
FT   STRAND       14     21
FT   STRAND       24     30
FT   STRAND       36     42
FT   HELIX        58     68
FT   STRAND       77     81
FT   STRAND       88     92
FT   STRAND       95     97
FT   HELIX        98    102
FT   HELIX       113    130
FT   HELIX       140    142
FT   STRAND      143    145
FT   STRAND      151    153
FT   HELIX       157    159
FT   TURN        161    163
FT   HELIX       181    184
FT   HELIX       192    208
FT   HELIX       218    229
FT   TURN        234    236
FT   STRAND      237    239
FT   HELIX       257    260
FT   HELIX       266    276
FT   TURN        280    282
FT   HELIX       286    290
FT   HELIX       293    295
FT   STRAND      297    299
FT   STRAND      304    307
SQ   SEQUENCE   346 AA;  39038 MW;  0A94BFA7DD416CEB CRC64;
     MALDVKSRAK RYEKLDFLGE GQFATVYKAR DKNTNQIVAI KKIKLGHRSE AKDGINRTAL
     REIKLLQELS HPNIIGLLDA FGHKSNISLV FDFMETDLEV IIKDNSLVLT PSHIKAYMLM
     TLQGLEYLHQ HWILHRDLKP NNLLLDENGV LKLADFGLAK SFGSPNRAYT HQVVTRWYRA
     PELLFGARMY GVGVDMWAVG CILAELLLRV PFLPGDSDLD QLTRIFETLG TPTEEQWPDM
     CSLPDYVTFK SFPGIPLHHI FSAAGDDLLD LIQGLFLFNP CARITATQAL KMKYFSNRPG
     PTPGCQLPRP NCPVETLKEQ SNPALAIKRK RTEALEQGGL PKKLIF
//
